Factors Affecting Mortality in Covid-19 Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06043115 |
Recruitment Status :
Completed
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
COVID-19 Pneumonia Mortality | Other: covid-19 survival cohort Other: covid-19 mortality cohort |
It was designed as a retrospective cohort study in which patients with a diagnosis of COVID-19 hospitalized in the ICU between 11 March 2020 and 31 March 2022 were included.
Patients aged ≥18 years with a confrmed diagnosis of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection by a positive real-time reverse-transcription polymerase chain reaction test (RT-PCR) on a nasopharyngeal swab or or endotracheal aspirate were included in the present study. The study data collected from the patient record at ICU admission included demographic characteristics (age, sex, body mass index), smoking history, comorbidities, vaccination status, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Sequential Organ Failure Assessment (SOFA) score, laboratory findings, blood gas analysis (PaO2/FiO2 ratio), oxygen device method, lenght of stay ICU and hospital duration and COVID-19 related complications. Laboratory findings included a complete blood count, coagulation testing, D-dimer, blood chemical analysis, C-reactive protein (CRP), assessment of liver and renal function, procalcitonin, and microbial cultures results. Additional adjunctive support, including extracorporeal membrane oxygenation (ECMO), prone positioning, renal replacement therapy (RRT) were documented daily. Information on patient-specific therapies, such as administration of hydroxychloroquine, antivirals, convalescent plasma and plasmapheresis was also collected.
Study Type : | Observational |
Actual Enrollment : | 619 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Factors Affecting Mortality in Covid-19 Disease |
Actual Study Start Date : | May 11, 2022 |
Actual Primary Completion Date : | November 30, 2022 |
Actual Study Completion Date : | December 15, 2022 |
Group/Cohort | Intervention/treatment |
---|---|
covid-19 survival cohort
consists of surviving patients
|
Other: covid-19 survival cohort
consists of surviving patients |
covid-19 mortality cohort
consists of deceased patients
|
Other: covid-19 mortality cohort
consists of deceased patients |
- factors affecting mortality in COVID-19 [ Time Frame: 11 March 2020 -31 March 2022 ]clinical and laboratory characteristics of COVID-19 patients in mortality of ICU.
- difference between the pandemic waves [ Time Frame: 11 March 2020-31 March 2022 ]mortality rate of ICU, clinical and laboratory characteristics of COVID-19 patients according to pandemic waves
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients aged ≥18 years with a confrmed diagnosis of the severe acute respiratory syndrome coronavirus-2 infection by a positive real-time reverse-transcription polymerase chain reaction test
Exclusion Criteria:
- Patients whose SARS-CoV-2 RT-PCR test was negative
- Chest computed tomography findings or symptoms were not compatible with COVID-19
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06043115
Turkey | |
Akdeniz University School of Medicine, Department of Anesthesiology and Intensive Care, Turkey | |
Antalya, Turkey |
Principal Investigator: | Burcu Ozer, MD | Akdeniz University School of Medicine, Department of Anesthesiology and Reanimation, Turkey |
Responsible Party: | Melike Cengiz, MD,Professor Doctor, Akdeniz University |
ClinicalTrials.gov Identifier: | NCT06043115 |
Other Study ID Numbers: |
Akdeniz University Faculty |
First Posted: | September 21, 2023 Key Record Dates |
Last Update Posted: | September 21, 2023 |
Last Verified: | September 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |